Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at UT Southwestern Medical Center, shared a post by Oscar Tahuahua, Medical Oncology Fellow at the National Cancer Institute of Mexico, on X, adding:
“Like PROSPECT, the RT arm in CONVERT received less chemo. Not only was planned # of cycles less (6 v 8), but ~25% never received ANY multiagent chemo. Hence trial compensates for RT omission by delivering more chemo.
In that light, similar DFS/OS (even w N2) actually remarkable.”
Title: Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial
Authors: Wei-Jian Mei, Xiao-Zhong Wang, Xuan Zhang, Yue-Ming Sun, Chun-Kang Yang, Jun-Zhong Lin, Zu-Guang Wu, Rui Zhang, Wei Wang, Yong Li, Ye-Zhong Zhuang, Jian Lei, Xiang-Bin Wan, Ying-Kun Ren, Yong Cheng, Wen-Liang Li, Zi-Qiang Wang, Dong-Bo Xu, Xian-Wei Mo, Hai-Xing Ju, Sheng-Wei Ye, Jing-Lin Zhao, Hong Zhang, Yuan-Hong Gao, Zhi-Fan Zeng, Wei-Wei Xiao, Xiao-Peng Zhang, Yun-Feng Li, E Xie, Yi-Fei Feng, Jing-Hua Tang, Xiao-Jun Wu, Gong Chen, Li-Ren Li, Zhen-Hai Lu, De-Sen Wan, Jin-Xin Bei, Zhi-Zhong Pan, Jie-Hai Yu, Pei-Rong Ding
Read The Full Article.
Oscar Tahuahua on Neoadjuvant CAPOX Versus Chemoradiation in Rectal Cancer
